Effective treatment with icotinib in lung adenocarcinoma with EGFR and ALK co-alterations and brain metastasis

被引：4

作者：

Ye, Chenyang ^{[1
]}

Wang, Ji ^{[2
]}

Zheng, Shu ^{[1
]}

Chai, Ying ^{[3
]}

机构：

[1] Zhejiang Univ, Affiliated Hosp 2, Key Lab Canc Prevent & Intervent,Sch Med,Canc Ins, Natl Minist Educ,Prov Key Lab Mol Biol Med Sci, Hangzhou, Zhejiang, Peoples R China

[2] Zhejiang Univ, Dept Surg Oncol, Sir Run Run Shaw Hosp, Coll Med, Hangzhou, Zhejiang, Peoples R China

[3] Zhejiang Univ, Dept Thorac Surg, Sch Med, Affiliated Hosp 2, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China

来源：

ONCOTARGETS AND THERAPY | 2016年 / 9卷

关键词：

lung cancer; brain metastasis; EGFR; ALK; icotinib; EML4-ALK FUSION GENE; CANCER; CRIZOTINIB; GEFITINIB; MUTATION; REARRANGEMENTS;

D O I：

10.2147/OTT.S121923

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

We report a rare case of advanced lung cancer with epidermal growth factor receptor and anaplastic lymphoma kinase co-alterations and brain metastasis, in which icotinib treatment was effective for both the primary lung tumor and the brain metastasis. The patient achieved important clinical remission with a progression-free survival for two years. Our treatment strategy appears to be a promising therapeutic approach for this subgroup of patients.

引用

页码：6605 / 6608

页数：4

共 50 条

[21] Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
Kejun Liu
Guanming Jiang
Ailing Zhang
Zhuanghua Li
Jun Jia
[J]. BMC Cancer, 20
[22] Lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement
Caliez, J.
Monnet, I.
Pujals, A.
Rousseau-Bussac, G.
Jabot, L.
Boudjemaa, A.
Leroy, K.
Chouaid, C.
[J]. REVUE DES MALADIES RESPIRATOIRES, 2017, 34 (05) : 576 - 580
[23] Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma
Cai, Weijing
Lin, Dongmei
Wu, Chunyan
Li, Xuefei
Zhao, Chao
Zheng, Limou
Chuai, Shannon
Fei, Ke
Zhou, Caicun
Hirsch, Fred R.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (32) : 3701 - +
[24] Icotinib, an effective treatment option for patients with lung adenocarcinoma harboring compound EGFR L858R and A871G mutation
Lin-ling Jin
Zhen-zhen Wu
Yan-li Wang
Dong-sheng Chen
Si Li
Mingzhe Xiao
Xin Zhao
[J]. Investigational New Drugs, 2021, 39 : 1419 - 1421
[25] Croatian Caucasians with lung adenocarcinoma harbouring EGFR mutations with and without brain metastasis
Sreter, Katherina
Kukulj, Suzana
Smojver-Jezek, Silvana
Seiwerth, Sven
Jakopovic, Marko
Samarzija, Miroslav
[J]. EUROPEAN RESPIRATORY JOURNAL, 2017, 50
[26] BACE1 cleaves EGFR to drive lung adenocarcinoma brain metastasis
Chafe, Shawn C.
Zhai, Kui
Singh, Sheila K.
[J]. MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
[27] Lung adenocarcinoma patient with an EGFR kinase domain duplication (KDD) and the response to icotinib
Zhu, You-Cai
Wang, Wen-Xian
Xu, Chun-Wei
Tan, Qing-He
Li, Jian-Ying
Zhuang, Wu
Song, Zheng-Bo
Du, Kai-Qi
Chen, Gang
Lv, Tang-Feng
Song, Yong
[J]. JOURNAL OF THORACIC DISEASE, 2018, 10 (05) : E359 - E363
[28] Icotinib, an effective treatment option for patients with lung adenocarcinoma harboring compound EGFR L858R and A871G mutation
Jin, Lin-ling
Wu, Zhen-zhen
Wang, Yan-li
Chen, Dong-sheng
Li, Si
Xiao, Mingzhe
Zhao, Xin
[J]. INVESTIGATIONAL NEW DRUGS, 2021, 39 (05) : 1419 - 1421
[29] Sequential EGFR mutation and ALK rearrangement in adenocarcinoma lung, with rare metastasis to bilateral breast, ovary and endometrium
Anjali, V. R.
Pandey, Rambha
Srivastava, Astha
Rajeshwari, Madhu
Pandey, Durgatosh
Sharma, M. C.
[J]. RESPIRATORY MEDICINE CASE REPORTS, 2019, 28
[30] Examining the Effect of ALK and EGFR Mutations on Survival Outcomes in Surgical Lung Brain Metastasis Patients
Mannam, Sneha Sai
Bray, David P.
Nwagwu, Chibueze D.
Zhong, Jim
Shu, Hui-Kuo
Eaton, Bree
Sudmeier, Lisa
Goyal, Subir
Deibert, Christopher
Nduom, Edjah K.
Olson, Jeffrey
Hoang, Kimberly B.
[J]. CANCERS, 2023, 15 (19)

← 1 2 3 4 5 →